Edition:
United States

Lexicon Pharmaceuticals Inc (LXRX.OQ)

LXRX.OQ on NASDAQ Stock Exchange Global Select Market

13.88USD
3:59pm EST
Change (% chg)

$0.04 (+0.29%)
Prev Close
$13.84
Open
$13.86
Day's High
$14.07
Day's Low
$13.71
Volume
158,067
Avg. Vol
231,756
52-wk High
$19.50
52-wk Low
$7.66

LXRX.OQ

Chart for LXRX.OQ

About

Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company's telotristat etiprate, is an orally delivered... (more)

Overall

Beta: 0.59
Market Cap(Mil.): $1,439.86
Shares Outstanding(Mil.): 104.04
Dividend: --
Yield (%): --

Financials

  LXRX.OQ Industry Sector
P/E (TTM): -- 44.85 30.38
EPS (TTM): -0.30 -- --
ROI: -6.49 -1.38 14.86
ROE: -11.62 -1.07 16.28

BRIEF-Lexicon Pharmaceuticals reports Q3 loss per share $0.35

* Lexicon Pharmaceuticals provides clinical pipeline update and reports 2016 third quarter financial results

Nov 01 2016

BRIEF-Lexicon announces publication Of TELESTAR study results for Telotristat Ethyl

* Results from pivotal phase 3 clinical study of Telotristat Ethyl show clinical benefit in patients with carcinoid syndrome

Oct 31 2016

BRIEF-Lexicon Pharmaceuticals agrees to buy remaining obligations to Symphony Icon

* Lexicon Pharmaceuticals announces agreement to buy out remaining obligations to Symphony Icon

Oct 05 2016

BRIEF-Lexicon Pharmaceuticals Q2 loss per share $0.37

* Q2 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S

Aug 04 2016

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $31.46 -0.31
Roche Holding Ltd. (ROG.S) CHF232.20 -1.30
Roche Holding Ltd. (RO.S) CHF234.80 -1.30
Merck & Co., Inc. (MRK.N) $61.81 -0.72
Bayer AG (BAYGn.DE) €101.05 -1.45
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €74.84 -0.78
Eli Lilly and Co (LLY.N) $76.32 -0.49
Abbott Laboratories (ABT.N) $40.34 -0.12
Bristol-Myers Squibb Co (BMY.N) $50.00 +0.77

Earnings vs. Estimates